Zorevunersen Shows Promise for Dravet Syndrome

An international clinical trial led by University College London and Great Ormond Street Hospital has shown that Zorevunersen, an experimental treatment developed by Stoke Therapeutics in collaboration with Biogen, is safe and highly effective in reducing seizures in children with Dravet syndrome. The drug, administered via lumbar puncture, targets the underlying genetic cause of the condition by increasing the protein levels from the healthy SCN1A gene. Patients in the trial experienced up to a 91% reduction in seizures and improved quality of life. These promising results, published in The New England Journal of Medicine, support further evaluation in an ongoing Phase Three study, offering significant hope for families affected by this severe form of epilepsy.